Short-Term Results of Switch from Conbercept to Bevacizumab or Ranibizumab in Eyes with Persistent Neovascular Age-Related Macular Degeneration
Changes of the mean cPEDH in eyes with persistent nAMD. cPEDH did not change statistically significantly during the treatment of IVC. But it significantly reduced after switching to IVR or IVB from 169.3 ± 230.6 μm to 130.5 ± 180.2 μm at T3 and 114.6 ± 142.6 μm at T4. The mean change of cPEDH from T2 was significantly larger in IVR subgroup than in IVB subgroup at both T3 () and T4 (). cPEDH, PED height at foveal center; PED, pigmented epithelial detachment; IVC, intravitreal injections of conbercept; IVB, intravitreal injection of bevacizumab; IVR, intravitreal injection of ranibizumab; T0, baseline visit; T1, 1 month after the first ICV; T2, 1 month after 3 monthly IVC; T3, 1 month after the first IVR or IVB; T4, 1 month after the last IVR or IVB.
Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.